Lapatinib works by binding to the tyrosine kinase domains of the EGFR and HER2 receptors, preventing their activation. This blockade inhibits downstream signaling pathways that promote cell proliferation and survival. By targeting these receptors, lapatinib can effectively slow down or stop the growth of cancer cells that overexpress HER2 or have mutations in the EGFR pathway.
